Our study supports this finding as, in two of the six studied patients, the RUNX1 gene is affected by mutations in all tumor steps and the patients experienced progression of the disease in spite of treatment with the aromatase inhibitor Letrozole. This evidence concerns the gene CYP19A1 and neoplasm.